HPTN Studies

Our studies strive to prevent HIV acquisition and transmission through the use of antiretroviral drugs, interventions for substance use, behavioral risk reduction, and structural interventions. 

HPTN research studies are developed by protocol teams that include CTU investigators and recognized experts in HIV prevention. As study protocols are developed, they undergo a rigorous intra- and extra-Network review process that ensures compliance with current ethical guidelines and regulatory procedures. Each Study Protocol is available once version 1.0 is approved and distributed to the performance sites.

 

Study Snapshot

Study Timelines

Filter studies by:

HPTN 094 (38715)

INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care.

Participants Off Study and Primary Analysis Completed

Integrated Strategy

HVTN 805/HPTN 093 (38691)

Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who initiated ART in early HIV infection after having received VRC01 or placebo in HVTN 703/HPTN 081

Participants Off Study and Primary Analysis Completed

Other

HPTN 084-01 (38655)

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV among Adolescent Females – A Sub-study of HPTN 084

Participants Off Study and Primary Analysis Completed

PrEP

HPTN 083-01 (38654)

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV among Adolescent Males – A sub-study of HPTN 083

Closed to Follow Up

PrEP

HVTN 136/HPTN 092 (38634)

A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous infusion or via subcutaneous injections in healthy, HIV-uninfected adult participants.

Closed to Follow Up

Antibody Mediated Prevention

HPTN 091 (38695)

Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation to Prevent HIV Acquisition and HIV Transmission for TGW in the Americas: A Vanguard Feasibility and Acceptability Study

Closed to Accrual

Integrated Strategy

HVTN 130/HPTN 089 (38531)

A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adult participants

Concluded

Antibody Mediated Prevention

HVTN 127/HPTN 087 (38458)

A multicenter, randomized, partially blinded phase 1 clinical trial to evaluate the safety and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected adults.

Concluded

Antibody Mediated Prevention